Capricor Therapeutics
CAPR
20 hedge funds and large institutions have $3.23M invested in Capricor Therapeutics in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 4 closing their positions.
0.89% less ownership
Funds ownership: 9.46% → 8.58% (-0.89%)
9% less funds holding
Funds holding: 22 → 20 (-2)
16% less capital invested
Capital invested by funds: $3.84M → $3.23M (-$613K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$90.9K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$23K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$4.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$56K |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$53K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$45K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$16K |
| 5 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$13.4K |
CAPR Hedge Fund Activity: Q1 2018 in Review
20 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2018, worth a combined $3.23M — down 16% from $3.84M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CAPR and 2 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 1 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $90.9K. The largest seller was Wells Fargo, exiting entirely with an estimated $56K sold.
- 20 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2018, down from 22 in Q4 2017.
- Funds reported $3.23M of Capricor Therapeutics stock for Q1 2018, down 16% quarter-over-quarter.
- 2 funds opened new Capricor Therapeutics positions in Q1 2018 and 4 closed out, a net change of -2 holders.
- The largest Capricor Therapeutics buyer in Q1 2018 was Virtu Financial, an estimated $90.9K added.
- The largest Capricor Therapeutics seller in Q1 2018 was Wells Fargo, an estimated $56K sold.
Based on aggregated 13F filings for Q1 2018.